NCT00234078View on ClinicalTrials.gov

Dose-response Study of OPC-12759 Ophthalmic Suspension

PHASE2CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

March 31, 2007

Conditions
Dry Eye Syndromes
Interventions
DRUG

0.5% OPC-12759

DRUG

1% OPC-12759

DRUG

2% OPC-12759

DRUG

placebo

Trial Locations (1)

Unknown

Otsuka Pharmaceutical Co., Ltd., Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT00234078 - Dose-response Study of OPC-12759 Ophthalmic Suspension | Biotech Hunter | Biotech Hunter